Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Non-Current Deffered Revenue: 2014-2022

Historic Non-Current Deffered Revenue for Capricor Therapeutics (CAPR) over the last 3 years, with Dec 2022 value amounting to $9.5 million.

  • Capricor Therapeutics' Non-Current Deffered Revenue fell 90.32% to $953,470 in Q3 2023 from the same period last year, while for Sep 2023 it was $953,470, marking a year-over-year decrease of 90.32%. This contributed to the annual value of $9.5 million for FY2022, which is N/A change from last year.
  • According to the latest figures from FY2022, Capricor Therapeutics' Non-Current Deffered Revenue is $9.5 million, which was up 938.77% from $911,458 recorded in FY2015.
  • In the past 5 years, Capricor Therapeutics' Non-Current Deffered Revenue ranged from a high of $9.5 million in FY2022 and a low of $9.5 million during FY2022.
  • Moreover, its 1-year median value for Non-Current Deffered Revenue was $9.5 million (2022), whereas its average is $9.5 million.